Annual FCF
-$27.38 M
-$1.49 M-5.77%
December 31, 2023
Summary
- As of February 8, 2025, RGLS annual free cash flow is -$27.38 million, with the most recent change of -$1.49 million (-5.77%) on December 31, 2023.
- During the last 3 years, RGLS annual FCF has fallen by -$14.83 million (-118.23%).
- RGLS annual FCF is now -376.80% below its all-time high of $9.89 million, reached on December 31, 2010.
Performance
RGLS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$9.48 M
+$2.24 M+19.14%
September 30, 2024
Summary
- As of February 8, 2025, RGLS quarterly free cash flow is -$9.48 million, with the most recent change of +$2.24 million (+19.14%) on September 30, 2024.
- Over the past year, RGLS quarterly FCF has increased by +$2.24 million (+19.14%).
- RGLS quarterly FCF is now -397.18% below its all-time high of $3.19 million, reached on December 31, 2020.
Performance
RGLS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$36.36 M
-$2.66 M-7.89%
September 30, 2024
Summary
- As of February 8, 2025, RGLS TTM free cash flow is -$36.36 million, with the most recent change of -$2.66 million (-7.89%) on September 30, 2024.
- Over the past year, RGLS TTM FCF has dropped by -$2.66 million (-7.89%).
- RGLS TTM FCF is now -560.68% below its all-time high of -$5.50 million, reached on March 31, 2012.
Performance
RGLS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
RGLS Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.8% | +19.1% | -7.9% |
| 3 y3 years | -118.2% | -49.2% | -38.3% |
| 5 y5 years | +36.8% | -93.5% | -195.4% |
RGLS Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.3% | at low | -53.0% | +19.1% | -49.2% | at low |
| 5 y | 5-year | -118.2% | at low | -397.2% | +19.1% | -197.1% | at low |
| alltime | all time | -376.8% | +53.7% | -397.2% | +49.7% | -560.7% | +46.1% |
Regulus Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.48 M(-19.1%) | -$36.36 M(+7.9%) |
| Jun 2024 | - | -$11.72 M(+30.6%) | -$33.70 M(+19.4%) |
| Mar 2024 | - | -$8.97 M(+44.8%) | -$28.24 M(+3.1%) |
| Dec 2023 | -$27.38 M(+5.8%) | -$6.20 M(-9.1%) | -$27.38 M(-0.4%) |
| Sep 2023 | - | -$6.82 M(+9.1%) | -$27.50 M(+0.3%) |
| Jun 2023 | - | -$6.25 M(-23.0%) | -$27.42 M(-0.4%) |
| Mar 2023 | - | -$8.12 M(+28.5%) | -$27.52 M(+6.3%) |
| Dec 2022 | -$25.89 M(+6.2%) | -$6.32 M(-6.2%) | -$25.89 M(-5.7%) |
| Sep 2022 | - | -$6.74 M(+6.0%) | -$27.44 M(+4.4%) |
| Jun 2022 | - | -$6.35 M(-2.0%) | -$26.30 M(+4.8%) |
| Mar 2022 | - | -$6.48 M(-17.6%) | -$25.10 M(+2.9%) |
| Dec 2021 | -$24.38 M(+94.3%) | -$7.87 M(+40.9%) | -$24.38 M(+83.1%) |
| Sep 2021 | - | -$5.59 M(+8.4%) | -$13.32 M(+8.8%) |
| Jun 2021 | - | -$5.16 M(-10.6%) | -$12.24 M(-0.6%) |
| Mar 2021 | - | -$5.76 M(-280.7%) | -$12.31 M(-1.9%) |
| Dec 2020 | -$12.55 M(-37.5%) | $3.19 M(-170.7%) | -$12.55 M(-39.6%) |
| Sep 2020 | - | -$4.51 M(-13.7%) | -$20.77 M(-1.8%) |
| Jun 2020 | - | -$5.23 M(-12.9%) | -$21.16 M(-2.2%) |
| Mar 2020 | - | -$6.00 M(+19.2%) | -$21.63 M(+7.8%) |
| Dec 2019 | -$20.07 M(-53.7%) | -$5.04 M(+2.8%) | -$20.07 M(+5.4%) |
| Sep 2019 | - | -$4.90 M(-14.1%) | -$19.05 M(-25.6%) |
| Jun 2019 | - | -$5.70 M(+28.6%) | -$25.62 M(-20.3%) |
| Mar 2019 | - | -$4.43 M(+10.4%) | -$32.13 M(-25.8%) |
| Dec 2018 | -$43.30 M | -$4.02 M(-65.0%) | -$43.30 M(-14.2%) |
| Sep 2018 | - | -$11.47 M(-6.1%) | -$50.47 M(-0.6%) |
| Jun 2018 | - | -$12.21 M(-21.7%) | -$50.76 M(-9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$15.60 M(+39.5%) | -$55.86 M(-5.5%) |
| Dec 2017 | -$59.09 M(+2.2%) | -$11.19 M(-4.9%) | -$59.09 M(-6.5%) |
| Sep 2017 | - | -$11.76 M(-32.1%) | -$63.18 M(-6.3%) |
| Jun 2017 | - | -$17.31 M(-8.1%) | -$67.42 M(+0.1%) |
| Mar 2017 | - | -$18.84 M(+23.3%) | -$67.35 M(+16.4%) |
| Dec 2016 | -$57.85 M(+12.8%) | -$15.28 M(-4.5%) | -$57.85 M(-3.8%) |
| Sep 2016 | - | -$15.99 M(-7.2%) | -$60.13 M(+6.6%) |
| Jun 2016 | - | -$17.24 M(+84.7%) | -$56.42 M(+14.8%) |
| Mar 2016 | - | -$9.34 M(-46.8%) | -$49.13 M(-4.2%) |
| Dec 2015 | -$51.29 M(+26.0%) | -$17.56 M(+43.0%) | -$51.29 M(+12.9%) |
| Sep 2015 | - | -$12.28 M(+23.5%) | -$45.42 M(+7.3%) |
| Jun 2015 | - | -$9.95 M(-13.4%) | -$42.35 M(-1.8%) |
| Mar 2015 | - | -$11.49 M(-1.7%) | -$43.11 M(+5.9%) |
| Dec 2014 | -$40.72 M(+39.6%) | -$11.70 M(+27.0%) | -$40.72 M(+5.7%) |
| Sep 2014 | - | -$9.21 M(-14.0%) | -$38.52 M(+13.2%) |
| Jun 2014 | - | -$10.71 M(+17.7%) | -$34.03 M(+9.7%) |
| Mar 2014 | - | -$9.10 M(-4.1%) | -$31.01 M(+6.3%) |
| Dec 2013 | -$29.16 M(+187.4%) | -$9.49 M(+101.2%) | -$29.16 M(+50.8%) |
| Sep 2013 | - | -$4.72 M(-38.7%) | -$19.34 M(+33.9%) |
| Jun 2013 | - | -$7.69 M(+6.0%) | -$14.44 M(+21.3%) |
| Mar 2013 | - | -$7.26 M(-2273.4%) | -$11.90 M(+17.3%) |
| Dec 2012 | -$10.15 M(-35.2%) | $334.00 K(+85.6%) | -$10.15 M(-3.2%) |
| Sep 2012 | - | $180.00 K(-103.5%) | -$10.48 M(-1.7%) |
| Jun 2012 | - | -$5.16 M(-6.3%) | -$10.66 M(+93.7%) |
| Mar 2012 | - | -$5.50 M | -$5.50 M |
| Dec 2011 | -$15.66 M(-258.3%) | - | - |
| Dec 2010 | $9.89 M | - | - |
FAQ
- What is Regulus Therapeutics annual free cash flow?
- What is the all time high annual FCF for Regulus Therapeutics?
- What is Regulus Therapeutics annual FCF year-on-year change?
- What is Regulus Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly FCF year-on-year change?
- What is Regulus Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Regulus Therapeutics?
- What is Regulus Therapeutics TTM FCF year-on-year change?
What is Regulus Therapeutics annual free cash flow?
The current annual FCF of RGLS is -$27.38 M
What is the all time high annual FCF for Regulus Therapeutics?
Regulus Therapeutics all-time high annual free cash flow is $9.89 M
What is Regulus Therapeutics annual FCF year-on-year change?
Over the past year, RGLS annual free cash flow has changed by -$1.49 M (-5.77%)
What is Regulus Therapeutics quarterly free cash flow?
The current quarterly FCF of RGLS is -$9.48 M
What is the all time high quarterly FCF for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly free cash flow is $3.19 M
What is Regulus Therapeutics quarterly FCF year-on-year change?
Over the past year, RGLS quarterly free cash flow has changed by +$2.24 M (+19.14%)
What is Regulus Therapeutics TTM free cash flow?
The current TTM FCF of RGLS is -$36.36 M
What is the all time high TTM FCF for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM free cash flow is -$5.50 M
What is Regulus Therapeutics TTM FCF year-on-year change?
Over the past year, RGLS TTM free cash flow has changed by -$2.66 M (-7.89%)